10th Annual
Cardiometabolic Health Congress

October 21-24, 2015    |   Boston, MA

The CMHC curriculum will provide the most effective, current strategies for the prevention, diagnosis, and management of type 2 diabetes, atherosclerosis, hypertension, dyslipidemia, obesity, thrombosis, chronic kidney disease, insulin resistance, hypertriglyceridemia and related comorbidities.

Learn More
10th annual cmhc

The 10th Annual Cardiometabolic Health Congress (CMHC)

Integrated management of all aspects of cardiometabolic risk is the only way to approach the rapidly growing epidemic of cardiovascular and metabolic disease. The 10th Annual Cardiometabolic Health Congress, October 21 - 24, 2015 in Boston, delivers the most comprehensive, state-of-the-art data and strategies aimed directly at the intersection of these diseases - imparting the scientific basis and practical clinical tools essential to combat cardiometabolic risk and the multitude of related comorbidities.

  • Largest cardiometabolic summit
  • Interactive case-based symposia
  • CME/CE Sessions – 27+ Credits
  • World-renowned faculty
  • Most current clinical data
  • Real world solutions
Register Now

Best of the
Health Congress

2015 Regional Conference Series
Convenient, 1-day CME Updates

Register Now

Saturday - March 28, 2015
Atlanta, GA


Saturday - May 2, 2015
Dallas, TX


Saturday - August 15, 2015
Las Vegas, NV


Online CME Activities

Did you miss the
Cardiometabolic Health Congress?

24-7 Access to Virtual Highlights & Mobile CME


What your colleagues are saying...


"This conference has it all, from emerging research to the latest clinical guidelines to putting that knowledge into everyday practice."

Atul Soreng, MD

"As a seasoned clinician, the CMHC is the best clinical practice educational conference I've ever attended!"

Nancy Allison, ARNP, CDE


Stay Connected

Your information stays private with us.
We will not share it with anyone else.

Speaker Spotlight

Jay Horton

Dr. Jay Horton

Jay D. Horton, MD, CMHC keynote speaker and lead researcher among the original teams that cloned the PCSK9 gene before its function was realized, talked with CMHC recently about the rapid development of PCSK9 inhibitors, the first of which, Regeneron/Sanofi's alirocumab, has just received FDA approval-just 12 years after the PCSK9 gene was identified

Learn More

Latest News

CME Challenge